Evidence map›Paper›PMID 29399580›Full record

ArticleClinical and experimental vaccine research2018

Immunogenicity of the nanovaccine containing intimin recombinant protein in the BALB/c mice.

Zahra Sadat Hosseini, Jafar Amani, Fahimeh Baghbani Arani, Shahram Nazarian, Mohammad Javad Motamedi, Fatemeh Shafighian

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental vaccine research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Demystifying particle-based oral vaccines.Expert opinion on drug delivery · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Zahra Sadat HosseiniDepartment of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.ORCID https://orcid.org/0000-0002-4686-4045
Jafar AmaniApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-5155-4738
Fahimeh Baghbani AraniDepartment of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.ORCID https://orcid.org/0000-0002-4304-2011
Shahram NazarianDepartment of Biology, Faculty of Science, Imam Hossain University, Tehran, Iran.ORCID https://orcid.org/0000-0002-4693-877X
Mohammad Javad MotamediGreen Gene Company, Tehran, Iran.ORCID https://orcid.org/0000-0002-6335-5584
Fatemeh ShafighianPharmaceutical Sciences Branch, Pharmaceutical Sciences Research Center, Islamic Azad University (IAUPS), Tehran, Iran.ORCID https://orcid.org/0000-0003-2749-9967
Islamic Azad University of Varamin · IRBaqiyatallah University of Medical Sciences · IRImam Hossein University · IRIslamic Azad University Pharmaceutical Sciences Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMATERIALS AND

methodsIntimin recombinant protein was expressed in pET28a vector with

resultsIntimin produced by chitosan nanoparticles improves immunological responses through the adjuvant nature of chitosan nanoparticles. Chitosan may be used as a carrier for transportation of the prescribed vaccine. Among the mice, encapsulated intimin could be able to provide suitable titers of IgG and IgA by the aid of chitosan nanoparticles. Results of mice challenge showed that decreased the bacterial shedding significantly.

conclusionResults showed that the chitosan nanovaccine with intimin protein may be used as a suitable candidate vaccine against

Indexed as

Chitosan nanoparticlesEscherichia coli O157:H7Hemolitic uremic syndromeIntimin

Identifiers

PMID29399580
PMCPMC5795045
OpenAlexW2786370222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.